The topic of alcohol and the liver is long overdue for re-evaluation. The authors of this book have clearly taken up this challenge. Human interest in alcohol dates back to the Neolithic period (circa 10,000 BC). Only a small amount of alcohol is found naturally in food. Therefore, humans have yet to adapt to the high quantities of alcohol consumed daily by alcohol abusers. Alcohol is a simple carbohydrate and is metabolised as a fuel. However, unlike more naturally occurring carbohydrates such as glucose, the pathways for its metabolism are not subject to the same checks and balances. Ethanol oxidation reduces NAD+, which starves reactions that depend on this substrate. This accounts for the accumulation of fat in alcoholic steatosis. Alcohol metabolism generates significant amounts of reactive oxygen species (ROS), which damages mtDNA and subsequently mitochondrial integrity. The authors provide several lines of evidence that link the clinical picture of alcoholic liver disease with mitochondrial damage. Other important topics highlighted in this book include histo-pathological aspects of the disease. Clinical assessment of nutrition and vitamin supplementation is addressed as well. The book concludes with the highly topical and controversial aspect of liver transplantation in patients with alcoholic liver disease.

Variceal Hemorrhage provides an update of the evidence concerning several aspects of variceal hemorrhage. The book features new information on natural history, diagnosis of esophageal varices, assessment of the risk of bleeding and identification of high risk groups and patients who may benefit or be harmed from different treatments. The volume also presents a critical analysis of the different steps in the management of acute variceal bleeding. Authored by the most prominent world experts in their areas of expertise, Variceal Hemorrhage serves as a very useful reference for gastroenterologists, GI surgeons, residents in internal medicine and physicians dealing with and interested in the different aspects of this severe medical emergency.

This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Aspects of these two diseases covered in the book include global epidemiology and risk factors, pathogenesis, animal models, hepatic and extra-hepatic malignancies, treatment models, and current and emerging therapies. Written by experts in the field, Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside is a valuable resource for gastroenterologists, pathologists, and hepatologists who treat patients with alcoholic and nonalcoholic fatty liver disease.

This comprehensive handbook is a "one-stop-shop" for all researchers involved in the field of alcohol-related harm at the whole body or cellular level. Over 100 chapters provide abundant information of a wide range of topics that extend from the evolutionary aspects of alcohol consumption and the prevalence of alcohol misuse to programmed cell death. Each chapter is highly illustrated with tables and figures making this a valuable reference for students, clinicians and researchers alike. *Over 100 chapters conveniently divided into 3 sections *Represents a 'one-stop-shop' of information with suitable indexing of the various pathways and processes *Each chapter is highly illustrated with tables as well as figures

For people with alcohol excess and liver disease, successful management must be two-fold with management of both their psychological/physical addiction to alcohol and their liver disease. Alcohol Abuse and liver disease, with its joint focus on hepatology and psychiatry, provides both hepatologists and psychiatrists of all levels with a practical, concise and didactic guide to the investigation and clinical management of those with alcohol-related problems. Edited by a practicing hepatologist in the UK and a practising specialist in psychiatry/substance abuse in the US, it covers areas such as: • Risk factors for alcoholic liver disease • Interaction of alcohol with other co-morbidities • Clinical assessment of alcohol intake • Detoxification and management of withdrawal • Psychotherapeutic and pharmaceutical interventions • Treatment of liver disease Key points, management diagrams and high-quality images are all be supported by the very latest in clinical guidelines from the major hepatology and psychiatry societies such as the APA, EPA, AASLD and EASL. With increasing emphasis on multi-disciplinary speciality care in this area, this is the ideal tool to consult in order to provide the best care possible care for what are very challenging patients to manage.

Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD.

Alcohol abuse is this culture's most important drug problem. Statistics indicate that it is exacting a great and relentlessly increasing toll of human suffering. It is clear that the problem is not being dealt with in any effective manner. At the invitation of the. Canadian Hepatic Foundation, many of the world's experts gathered in Toronto, May 14-15 1976, to focus attention on one of the most important aspects of the alcohol problem -alcohol induced liver damage. The epidemiology of alcohol induced liver disease was discussed and current views on the pathogenesis of the problem were reviewed. New insight into the pathological alterations of the liver was presented and some of our current therapeutic capabilities were discussed. Dr. Hans Popper summarized the Symposium and presented some of his views on those aspects of the problem which will require early attention by the research community. The Symposium achieved its immediate objective -that of bringing together the committed experts of various disciplines for an updating of our understanding of alcohol and the liver and for a discussion of new approaches to the problem. As a backdrop to the Symposium, however, was large writing on the wall to the effect that we are expending our research talents and efforts on a totally unnecessary problem. Right now we probably know enough and have sufficient resources at our disposal to solve the problem.

Explore this practical and step-by-step guide to managing liver transplant patients from leading international clinicians in Hepatology The newly revised Second Edition of Liver Transplantation: Clinical Assessment and Management delivers expert clinical guidance on best practices in managing the care of liver transplant patients. Authors are all experts in their field and cover a world-wide perspective. Organized in an accessible, stepwise fashion and packed with text features such as key points, the book covers all critical areas of each stage of the liver transplant journey, from assessment, to management on the list, to long term care. Readers will learn when to refer a patient for liver transplantation, how to assess a potential liver transplant recipient, learn the principles of the procedure and the long term management of the transplant recipient. Liver Transplantation provides the entire hepatology and surgical team the information required for a sound understanding of the entire procedure, from pre- to post-operative care and management. Clinically oriented and management-focused, the book is far more accessible than the liver transplant sections in traditional hepatology textbooks. Readers will also enjoy: A thorough discussion of when to refer a patient for liver transplantation, including general considerations and the use and abuse of prognostic models An exploration of the selection, assessment, and management of patients on the transplant list, including how to manage a patient with chronic liver disease while on the waiting list A treatment of liver transplantation for acute liver failure (ALF), including assessment and management of ALF patients on the transplant waiting list A discussion of care of the liver transplant recipient after the procedure in the short and long term Perfect for gastroenterologists, hepatologists, and surgeons and other health care professionals managing patients with liver disease who are awaiting, undergoing and following liver transplantation, Liver Transplantation: Clinical Assessment and Management will also earn a place in the libraries of medical students, residents, internal medicine physicians, and GI/Hepatology trainees and all health care professionals providing clinical care to people with liver disease, before, during and after transplantation.

Bridging the gap between basic scientific advances and the understanding of liver disease — the extensively revised new edition of the premier text in the field. The latest edition of The Liver: Biology and Pathobiology remains a definitive volume in the field of hepatology, relating advances in biomedical sciences and engineering to understanding of liver structure, function, and disease pathology and treatment. Contributions from leading researchers examine the cell biology of the liver, the pathobiology of liver disease, the liver’s growth, regeneration, metabolic functions, and more. Now in its sixth edition, this classic text has been exhaustively revised to reflect new discoveries in biology and their influence on diagnosing, managing, and preventing liver disease. Seventy new chapters — including substantial original sections on liver cancer and groundbreaking advances that will have significant impact on hepatology — provide comprehensive, fully up-to-date coverage of both the current state and future direction of hepatology. Topics include liver RNA structure and function, gene editing, single-cell and single-molecule genomic analyses, the molecular biology of hepatitis, drug interactions and engineered drug design, and liver disease mechanisms and therapies. Edited by globally-recognized experts in the field, this authoritative volume: Relates molecular physiology to understanding disease pathology and treatment Links the science and pathology of the liver to practical clinical applications Features 16 new “Horizons” chapters that explore new and emerging science and technology Includes plentiful full-color illustrations and figures The Liver: Biology and Pathobiology, Sixth Edition is an indispensable resource for practicing and trainee hepatologists, gastroenterologists, hepatobiliary and liver transplant surgeons, and researchers and scientists in areas including hepatology, cell and molecular biology, virology, and drug metabolism.

Alcohol abuse remains a significant problem world-wide. The most commonly affected organ remains the liver with a risk of alcoholic liver disease (ALD) which can range from asymptomatic to alcoholic hepatitis to alcoholic cirrhosis. In 2010, alcohol-attributable cirrhosis was responsible for 0.9% of all global deaths. Given the sheer magnitude of alcohol abuse and alcoholic liver disease, an update on this topic is pertinent and relevant. This issue will focus on a variety of topics including alcoholism, the pathogenesis of ALD, the spectrum of ALD, the pathology of ALD, and the long-term management of patients with ALD. Alcoholic hepatitis is a particular type of ALD with a high mortality. This issue will explore the syndrome of alcoholic hepatitis, its prognostic markers, and the available therapies. Because alcohol intake can influence so many other conditions of the liver (especially hepatitis C), articles in this issue will also explore the impact of alcohol abuse on other liver conditions. In addition, several other topics such as nutritional therapy for ALD, ALD and liver cancer, and ALD and infection risk will be explored. Also, even though it is quite controversial, we will also explore liver transplant as a therapy for alcoholic liver disease including alcoholic hepatitis.